A vaporization device includes a first portion and a second portion. The first portion includes a first body defining a first interior volume, a first half of a split-pod, a second half of a split-pod, an opening, a first heating apparatus, and a second heating apparatus. The first half of the split-pod is configured to hold a nicotine-containing liquid. The second half of the split-pod is configured to hold a non-nicotine-containing liquid. The opening separates the first half from the second half of the split-pod. The first heating apparatus is dedicated to the first half. The second heating apparatus is dedicated to the second half. The second portion includes a second body defining a second interior volume and a computing system. The computing system is disposed within the second interior volume. The computing system is configured to vary an amount of current supplied to the first and second heating apparatuses.

Injection device comprising a tubular elongated main body, a needle shield slidably arranged in said main body, a needle shield link slidably connected to said needle shield, a cartridge containing medicament arranged in said main body, a needle connected to said cartridge, a plunger operatively arranged to said cartridge for ejecting said medicament through said needle and arranged on its upper part with a number of outwardly extending stop members, spring means arranged to said plunger for operating said plunger, a dose activating means, a needle shield spring surrounding the needle shield link. The injection device is capable of setting and delivering a certain preset dose.

The aerosol-generating article is capable of being used with an electrically-operated aerosol-generating device. The aerosol-generating article is a consumable article having an outlet end, a distal end upstream from the outlet end, and a mid-point located an equal distance between the outlet end and the distal end. The article includes a first volatile liquid substrate contained within a first frangible capsule, the frangible capsule being located between the distal end and the mid-point, and a second volatile liquid substrate contained within a second frangible capsule, the second frangible capsule being located between the distal end and the mid-point. The article also includes a liquid retention medium, at least a portion the liquid retention medium being located between the distal end and the mid-point, wherein the article is configured to allow air to be drawn through the article from the distal end to the outlet end.

A nasal inhaler for the inhalation of inhalable substances comprise: a canister having an interior reservoir containing pressurised inhalable substances including fluid; a metering valve including a metering chamber and a valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas located within the metering chamber is replaced with liquid from the interior reservoir.

An inhaler (10) has a main body for accommodating a medicament reservoir (84), a canister fire system for moving a canister (50) to release a dose in response to air flow, a cap housing (12) for enclosing the canister fire system and canister within an interior chamber defined by the main body (14) and a cap housing, wherein a lock system (250) is provided for locking the cap housing on the main body.

Disclosed is an oral mucosa delivery system that allows a composition housed therein to be dispensed in different amount and/or for different duration. The delivery system may comprise a spray cap or an aerosol cap capable of controlling the delivery duration and/or amount by a mechanical or electronic means.

A nebuliser for nebulising liquid droplets, including: a housing; at least one piezoelectric substrate (2) accommodated within the housing and having a transducer surface (2a) upon which is located at least one electroacoustic transducer (48) for generating acoustic wave energy within the at least one piezoelectric substrate (2), and an opposing non-transducer surface (2b); a liquid supply system for supplying a liquid to at least one of the transducer and non-transducer surfaces, the liquid supply system including a reservoir (3) for accommodating the liquid, and at least one relatively rigid supply conduit in contact with the at least one piezoelectric substrate (2) for supplying the liquid from the reservoir (3) to the at least one piezoelectric substrate (2); and a sensor for detecting a volume of liquid on the at least one piezoelectric substrate (2).

The invention relates to an ultrasonic mist inhaler (100), comprising: a mouthpiece (1) for inhaling the mist, a liquid reservoir structure (2) comprising a liquid chamber (21) adapted to receive liquid to be atomized, a sonication chamber (22) in fluid communication with the liquid chamber (21), wherein at least part of the liquid reservoir structure (2) and the mouthpiece (1) form the sonication chamber (22).

A stand-alone chamber or multi-chamber inhalation system has at least two alternative vaporized test liquid supply systems for passive or self-administered delivery of vaporized test fluid and air to one or more test chambers, which can be passive or restraint chambers, based on operator selection of delivery on and off times in a passive mode or actuation of an actuator in the chamber by a test animal in a self-administered mode. In one case, a multiple inhalation chamber system has two or more separate test fluid delivery systems and provides options for selective passive uniform drug delivery to multiple chambers or selective delivery of two or more different drugs to different groups of chambers from different delivery systems so that two different drugs or different concentrations of delivered drugs can be tested simultaneously.

Pressurized canisters coated with poly(fluoroalkylene) polymer or a copolymer of poly(fluoralkylenes) and containing a formulation comprising one or more active pharmaceutical ingredients comprising umeclidinium or a salt thereof, vilanterol or a salt thereof, or a combination of two or more of the foregoing, poly(ethylene glycol), and a propellant, inhalers comprising the pressurized canister, as well as methods of using the pressurized canisters and inhalers.